Orchid Pharma Q2 Results FY27: Net Profit Rs 28.59 Cr Against Loss, Revenue Rs 341.27 Cr
- November 14, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Orchid Pharma Q2 Results FY27 were declared on 14 November 2026 on a Consolidated basis. In these quarterly results, revenue grew 76.35% YoY to Rs 341.27 Cr from Rs 193.52 Cr, and net profit came in at Rs 28.59 Cr against a loss of Rs 5.72 Cr a year earlier. The YoY growth in net profit is recorded at 599.83% in the filing data.
Orchid Pharma Ltd (ORCHPHARMA) Q2 Results FY27 announced on 14 November 2026, covering the company’s financial performance for the July to September quarter. The results date brings Orchid Pharma Q2 Results FY27 with consolidated results showing revenue of Rs 341.27 Cr and net profit (PAT) of Rs 28.59 Cr, compared with a loss in the same quarter last year.
This results analysis of Orchid Pharma Q2 Results covers the financial highlights, business drivers, outlook and risks, based on the filing declared on 14 November 2026. The Financial Highlights section that follows lists the full numbers, and the Univest Screener carries the same lines for ORCHPHARMA.
Click Here – Get Free Investment Predictions
Orchid Pharma Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 341.27 Cr | Rs 193.52 Cr | +76.35% YoY |
| Operating Profit | Rs 24.14 Cr | Rs -1.48 Cr | +1731.08% YoY |
| Net Profit (PAT) | Rs 28.59 Cr | Rs -5.72 Cr | +599.83% YoY |
Source: company filing for Orchid Pharma Q2 Results FY27, 14 November 2026. Figures in Rs Crore, Consolidated basis.
Key Takeaways from Orchid Pharma Q2 Results: What Stands Out
- Revenue: Revenue grew 76.35% to Rs 341.27 Cr from Rs 193.52 Cr in the same quarter of the previous year.
- Net profit: Net profit stood at Rs 28.59 Cr against a loss of Rs 5.72 Cr a year earlier, with YoY growth of 599.83% in the filing data.
- Operating Profit: Operating Profit was Rs 24.14 Cr versus a loss of Rs 1.48 Cr a year earlier, with YoY growth of 1731.08% in the filing data.
- Basis: The figures are consolidated results, reported with Orchid Pharma Q2 Results FY27 on 14 November 2026.
- Next: The performance analysis below sets revenue and the two profit lines side by side.
Orchid Pharma Q2 Results FY27: Performance Analysis
The performance analysis of Orchid Pharma Q2 Results shows all three headline lines moving higher year on year. Revenue of Rs 341.27 Cr is 76.35% above Rs 193.52 Cr, Operating Profit of Rs 24.14 Cr compares with a loss of Rs 1.48 Cr, and net profit of Rs 28.59 Cr compares with a loss of Rs 5.72 Cr in the comparison quarter.
Orchid Pharma Q2 Results FY27 show that the consolidated filing moved from losses to profits on both profit lines while revenue grew by about three quarters. A rise on such low or negative prior bases makes the percentages large, which is simple arithmetic on the supplied figures and not a claim about cause.
Investors following quarterly results will next check how the following filing compares with this higher base, and the Univest app tracks these lines for ORCHPHARMA. A reading of Orchid Pharma Q2 Results FY27 that stays with reported numbers keeps the results analysis factual, which is where the results analysis moves to the business factors.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – The results analysis points first to revenue, which grew 76.3% year on year to Rs 341.27 Cr in the latest quarter. Orchid Pharma Q2 Results FY27 therefore open with the largest revenue move among the quarterly results lines.
Return to Profit – The company returned to a net profit of Rs 28.59 Cr from a loss in the comparison quarter, and net profit margin improved to 8.4% from -3.0%. The disclosed data confirms the change but does not establish a specific cause.
Revenue Record – Revenue has risen in each of the last 4 quarters. This disclosed run sits alongside the quarterly lines, and the next section turns to the FY27 outlook.
FY27 Outlook After Orchid Pharma Q2 Results
FY27 full-year results will depend on the quarters still to be reported and on later disclosures after the results date. The September quarter net profit of Rs 28.59 Cr is one data point within the year, and this results analysis treats it as such. Readers can follow how each new filing from ORCHPHARMA adds to the FY27 record by using the same lines each quarter.
Anyone comparing Orchid Pharma Q2 Results FY27 with later filings can keep the same consolidated basis, so revenue, Operating Profit and net profit remain comparable across quarters. The next section looks at the risks that the disclosed data highlights, because a rise in the quarterly lines does not remove them.
Key Risks to Watch After Orchid Pharma Q2 Results FY27
Low Return on Equity
Return on equity was low at 0.70% in FY26. Orchid Pharma Q2 Results FY27 therefore sit beside a full-year return figure that is modest, which is worth keeping in view next to the quarterly gains.
Modest Capital Returns
Return on capital employed was modest at 1.11% in FY26. A single quarter of YoY growth is best read against this full-year return when the next filing arrives.
Earnings Volatility
Quarterly net profit has been volatile, ranging from Rs -12.61 Cr to Rs 28.59 Cr over the last 5 quarters. A single figure is best read with neighbouring quarters, and the conclusion below ties the quarterly results back to that range.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Orchid Pharma Q2 Results FY27 show revenue growth of 76.35% and a net profit of Rs 28.59 Cr on a consolidated basis, against a loss a year earlier. These quarterly results leave later filings as the reference point, and the consolidated results are best read with the disclosed risks in view. A final look at Orchid Pharma Q2 Results should rest on the filing itself. Investors should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Orchid Pharma Q2 Results FY27
What are Orchid Pharma Q2 Results FY27?
Ans. Orchid Pharma Q2 Results FY27 are the consolidated quarterly results for July to September 2026, declared on the results date of 14 November 2026, so the Quick Answer and Financial Highlights carry the headline numbers.
What is the results date for Orchid Pharma Q2 Results FY27?
Ans. The results date is 14 November 2026, when Orchid Pharma declared its Q2 FY27 numbers, alongside which the opening paragraphs of this results analysis show the same date for the quarter.
What revenue was reported in Orchid Pharma Q2 Results FY27?
Ans. Orchid Pharma reported revenue of Rs 341.27 Cr in the quarter, compared with Rs 193.52 Cr a year earlier, which means the Performance Analysis section shows growth of 76.35%.
What net profit was reported in Orchid Pharma Q2 Results FY27?
Ans. Net profit was Rs 28.59 Cr for Orchid Pharma in the quarter, compared with a loss of Rs 5.72 Cr a year earlier, so the Key Takeaways section records YoY growth of 599.83%.
How much YoY growth did revenue show in Orchid Pharma Q2 Results FY27?
Ans. Revenue showed YoY growth of 76.35%, rising from Rs 193.52 Cr to Rs 341.27 Cr, while the Performance Analysis section explains how this compares with the two profit lines.
Did net profit rise or fall in Orchid Pharma Q2 Results?
Ans. Net profit rose in Orchid Pharma Q2 Results, moving from a loss of Rs 5.72 Cr to Rs 28.59 Cr, as shown in the Financial Highlights table, which also lists the revenue and Operating Profit lines.
What was the Operating Profit in Orchid Pharma Q2 Results FY27?
Ans. Operating Profit was Rs 24.14 Cr against a loss of Rs 1.48 Cr a year earlier, so the Performance Analysis section describes the percentage move as large because of the negative prior base.
Are Orchid Pharma Q2 Results consolidated results or standalone results?
Ans. Orchid Pharma Q2 Results are consolidated results, because the filing was declared on a Consolidated basis, so the opening paragraphs and the Conclusion both refer to the consolidated figures.
What business factors shaped Orchid Pharma Q2 Results FY27?
Ans. The disclosed business factors are revenue growth of 76.3%, a return to a net profit of Rs 28.59 Cr and revenue rising in each of the last 4 quarters, as set out in the Key Business Factors section.
What are the key risks after Orchid Pharma Q2 Results FY27?
Ans. The key risks are a return on equity of 0.70%, a return on capital employed of 1.11% and volatile quarterly net profit between Rs -12.61 Cr and Rs 28.59 Cr, as the Key Risks section explains.
What is the outlook after Orchid Pharma Q2 Results?
Ans. FY27 full-year results will depend on the quarters still to be reported, which means the September quarter net profit of Rs 28.59 Cr is one data point, as the Outlook section explains.
Where can I find the complete Orchid Pharma Q2 Results FY27 data?
Ans. The complete figures sit in the Financial Highlights table above, alongside the Univest Screener, which lists revenue and net profit for ORCHPHARMA so readers can compare the consolidated results across quarters.
